Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment.
D000293:Adolescent; D000578:Amidines / Q000627:therapeutic use*; D000666:Amphotericin B / Q000627:therapeutic use*; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use; D005260:Female; D005942:Gluconates / Q000627:therapeutic use; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D007109:Immunity; D007896:Leishmaniasis / Q000188:drug therapy*; D011319:Primaquine / Q000627:therapeutic use; D002727:Proguanil / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000627:therapeutic use*
D000578:Amidines; D000981:Antiprotozoal Agents; D005942:Gluconates; D013451:Sulfonic Acids; D006118:Griseofulvin; D000666:Amphotericin B; D002738:Chloroquine; D000965:Antimony; D011319:Primaquine; D002727:Proguanil